Pregabalin Capsule
Product Images NDC 68788-8472

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-8472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Capsules 50mg Cv (7f29991e 3bf5 4e48 8fa3 6d4e932ed6de 00)

Label for Pregabalin Capsules 50 mg by Preferred Pharmaceuticals Inc. The label states it is generic for Lyrica, with each capsule containing 50 mg pregabalin. Manufacturer listed is Hetero Labs Limited. The label includes storage instructions and cautions about federal law prohibiting drug transfer. It also has directions sections in English and Spanish.*

FDA Label Image

Logo (Logo)

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day with placebo, illustrating trends in patient pain improvement across these doses.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A survival curve chart showing the estimated percentage of subjects without LTR (likely treatment response) over days up to 180. Two curves are displayed: one for Pregabalin and one for Placebo, with Pregabalin maintaining a higher percentage of subjects without LTR over time compared to Placebo.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved over time, from baseline to week 12 BOCF, for Pregabalin versus Placebo. The x-axis indicates the percent improved, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, also from 0 to 100. Pregabalin shows a higher percent of subjects improved across the range compared to Placebo.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percentage of subjects improved over time from baseline to Week 16 for Pregabalin versus placebo. The x-axis represents percent improvement from baseline to Week 16 based on BOCF, and the y-axis shows the percent of subjects improved, with lines for Pregabalin and placebo shown separately.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph showing percent of patients improved as a function of percent improvement in pain from baseline. Two data series are plotted: one for Pregabalin 100 mg taken three times a day and one for placebo. The vertical axis represents percent of patients improved; the horizontal axis represents percent improvement in pain from baseline, ranging from greater than 0 to 100 percent.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline. The graph includes curves for Pregabalin at 75 mg, 150 mg, and 300 mg doses taken two times a day, as well as a placebo group.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends for patient improvement across a range of pain reduction percentages.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line chart showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo, illustrating patient improvement distribution across these categories.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) in studies E1 and E3 across different dosages including placebo, 600 mg/day, and others. The horizontal axis lists dosage groups, while the vertical axis shows responder rates from 10% to 60%. Bars in each group illustrate response percentages with statistical significance noted versus placebo.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A chart showing seizure reduction (median percentage change from baseline) plotted against dose in mg/day, comparing four study groups identified as Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, each represented by different symbols. P-values indicating statistical significance are displayed for various dose points, with placebo at zero dose for comparison.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph illustrating percent of patients improved versus percent improvement in pain from baseline. The graph compares different daily doses of Pregabalin (600 mg, 450 mg, 300 mg) and placebo, with dose groups shown in distinct line styles. Percent of patients who improved decreases as percent improvement in pain increases.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure diagram of Pregabalin, showing its molecular arrangement with functional groups including an amine (NH2) and carboxylic acid (COOH).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.